Evaluation of Obicetrapib on Antioxidant Levels in Plasma and HDL Particles of Healthy Volunteers

Launched by NEWAMSTERDAM PHARMA · May 13, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a medication called Obicetrapib to see if it can help improve the absorption of antioxidants in the blood and eye tissue of healthy volunteers. Antioxidants are important for protecting our bodies from damage, and this trial will compare Obicetrapib to a placebo, which is a substance that looks like the drug but has no active ingredients. The main goal is to find out if Obicetrapib can boost the levels of antioxidants in the body and the eyes.

To participate in this trial, individuals must be between the ages of 27 and 93 and have good vision (better than 20/60) in both eyes, whether they wear glasses or not. Participants will take either Obicetrapib or the placebo daily for four months and will visit the clinic every eight weeks for check-ups, blood tests, and eye exams to measure antioxidant levels. It’s important to note that people with type 2 diabetes, active liver disease, or significant eye problems will not be eligible for this study. This trial is not yet recruiting participants, but it aims to gather important information about how this medication might help improve health.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Visual acuity \> 20/60 in both eyes with or without corrective lenses
• Exclusion Criteria:
• • Type 2 diabetes
• • Active liver disease
• • Any clinically significant macular pathology